Volume 29, Number 3—March 2023
Research
Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal
Table 2
Crude and adjusted odds ratios of vaccine infection breakthrough in BA.5 case-patients compared with BA.2 SARS-CoV-2 case-patients, Portugal, epidemiologic weeks 17–23, 2022*
Category | BA.5, no. (%) | BA.2, no. (%) | Crude OR (95% CI) | Adjusted† OR (95% CI) |
---|---|---|---|---|
Vaccination status | ||||
Unvaccinated | 590 | 631 | Referent | Referent |
Complete primary vaccination | 2,530 | 2,434 | 1.11 (0.98–1.26) | 1.07 (0.93–1.23) |
Booster dose |
9,186 |
12,331 |
0.80 (0.71–0.89) |
0.96 (0.84–1.09) |
Previous infection | ||||
No | 11,073 | 14,536 | Referent | Referent |
Yes |
1,233 |
860 |
1.88 (0.71–2.06) |
1.44 (1.30–1.60) |
Vaccination status accounting for previous infection | ||||
Unvaccinated without previous infection | 468 (3.8) | 550 (3.6) | Referent | Referent |
Unvaccinated with previous infection | 122 (1.0) | 81 (0.5) | 1.77 (1.30–2.41) | 1.77 (1.26–2.49) |
Complete primary vaccination without previous infection | 1,802 (14.6) | 1,982 (12.9) | 1.07 (0.93–1.23) | 1.08 (0.92–1.26) |
Complete primary vaccination with previous infection | 729 (5.9) | 452 (2.9) | 1.90 (1.60–2.25) | 1.70 (1.40–2.05) |
Booster without previous infection | 8,805 (71.5) | 12,004 (78.0) | 0.86 (0.76–0.98) | 0.99 (0.86–1.14) |
Booster with the previous infection | 382 (3.1) | 327 (2.1) | 1.37 (1.13–1.66) | 1.18 (0.95–1.47) |
*OR, odds ratio. †Adjusted for age group, sex, region, and week of diagnosis.
1These first authors contributed equally to this article.
2These authors contributed equally to this article.